Interrupting antiretroviral treatment needs particular care [9]

British Medical Journal

Volumn 322, Issue 7286, 2001, Pages 616-

  Sewell, W A C ^a   Mazhude, C ^a   Murdin Geretti, A ^a   Jones, S ^a   Easterbrook, P J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; DIET RESTRICTION; DRUG HALF LIFE; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MUTATION RATE; PHENOTYPE; PRIORITY JOURNAL; TREATMENT PLANNING; VIRUS MUTATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; PERIOPERATIVE CARE;

EID: 0035835905     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Risks of interruptinng drug treatment before surgery
2. Antiretroviral therapy 2000
3. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy